Dr Reddy's COO On US Derma Build-Up, One-Sided Biologics Norms
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories (DRL) appears to be building on plans for its differentiated dermatology and neurology formulations in the US after gains on the approvals front.
You may also be interested in...
Psoriasis Sprays: Niche Opportunities?
Expanding treatment options for psoriasis highlight how some firms are developing innovative "lower risk" assets that use established active ingredients but could provide benefits to specific patient segments.
Early Strides for Takeda’s Qdenga In Brazil, India Deal Adds New Dimension
Takeda’s head of multi-country organization, India and Southeast Asia, Dion Warren, tells Scrip how things are shaping for Qdenga in Brazil’s public vaccination program and outlines the contours, including pricing aspects, of the deal with Biological E for the dengue vaccine. The US IND application for the jab is still open.
Obituary: Ranjit Shahani, Ex-Novartis India Chief Who ‘Traveled Light’
Industry veteran and mentor to many, Ranjit Shahani steered Novartis India with seeming calm through a rocky phase when the Glivec patent case ruling didn't go the Swiss multinational's way - perhaps not unusual for someone who had seen the ebbs and flows of life closely when his parents moved to India as refugees from Pakistan.